Related Experiment Videos
Sildenafil and phosphodiesterase-5 inhibitors for heart failure
1Cardiopulmonary Unit, University of Milano, San Paolo Hospital, Via A. di Rudini, 8, 20142 Milano, Italy. marco.guazzi@unimi.it
Insights
Phosphodiesterase-5 (PDE5) inhibitors show promise for treating heart failure (HF) by enhancing nitric oxide signaling. Further research is needed to confirm their safety and effectiveness in HF patients.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Heart failure (HF) presents significant treatment challenges.
- Impaired nitric oxide (NO) signaling contributes to cardiac and vascular dysfunction in HF.
- Phosphodiesterase-5 (PDE5) inhibition offers a novel therapeutic strategy by increasing cyclic guanosine monophosphate (cGMP) levels.
Purpose of the Study:
- To explore the therapeutic potential of PDE5 inhibitors in heart failure.
- To evaluate the role of PDE5 inhibition in addressing pulmonary hypertension and myocardial dysfunction associated with HF.
Main Methods:
- Review of background studies on PDE5 inhibitors in HF.
- Analysis of basic research on myocardial effects of cGMP.
- Examination of human studies assessing acute PDE5 inhibition benefits.
Main Results:
- PDE5 inhibitors are a potential treatment for HF, particularly for pulmonary hypertension.
- Increased cGMP activity may offer direct myocardial benefits, counteracting adverse signaling pathways.
- Human studies indicate acute benefits on lung function, endothelial function, and exercise capacity.
Conclusions:
- PDE5 inhibition is a promising therapeutic avenue for heart failure.
- Larger controlled trials are essential to establish safety, tolerability, and impact on morbidity and mortality in diverse HF populations.
Abstract:
Treatment of heart failure (HF) is a challenging task. An impaired nitric oxide pathway contributes to several abnormal cardiac and vascular phenotypes typical of the failing cardiovascular system. Inhibition of phosphodiesterase-5 (PDE5) is a new therapeutic strategy for overexpressing nitric oxide signaling by increasing the availability of cyclic guanosine monophosphate (cGMP). A number of background studies support the use of PDE5 inhibitors in HF. Treatment of pulmonary hypertension secondary to left ventricular dysfunction appears to be a primary target by virtue of the high PDE5 selectivity for the pulmonary circulation. Basic studies suggest that increased cGMP activity by PDE5 inhibition has potentially favorable direct myocardial effects that may block adrenergic, hypertrophic, and proapoptotic signaling. Furthermore, studies in humans have underscored the benefits of acute PDE5 inhibition on lung diffusion capacity, systemic endothelial function, muscle perfusion, and exercise performance. Despite promising initial data, larger controlled trials are necessary to define the safety, tolerability, and potential impact of PDE5 inhibitors on morbidity and mortality across the wide spectrum of patients with HF.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:30Heart Failure V: Medical Management
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: β-Blockers
01:22Heart Failure VI: Adjunct Therapies
01:22Heart Failure Drugs: Diuretics